Bionano genomics news.

About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Bionano Genomics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies. News Coverage …Dec 4, 2023 · Over the past 30 days, the shares of Bionano Genomics Inc (NASDAQ:BNGO) have changed 24.81%. Short interest in the company has seen 7.08 million shares shorted with days to cover at 6.06. Wall Street analysts have a consensus price target for the stock at $12.33, which means that the shares’ value could jump 86.54% from current levels. Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano Genomics, …Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD. SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories …

Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ...

Oct 11, 2023 · SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 (the “Registered Notes”) and warrants (the “Registered Warrants”) to purchase 21,660,650 shares of its common stock in a registered offering, a...

Automate Data Display for Powerful Insights. VIA software amplifies the story of your data by automatically generating powerful visualizations for enhanced variant contextualization across multiple variant types happening in the same genomic region. VIA allows you to drill down to single chromosome, gene, and nucleotide levels for deeper analysis.Company profile page for Bionano Genomics Inc including stock price, company news, executives, board members, and contact information.The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to …

Stock Price Forecast. The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.00, with a high estimate of 24.00 and a low estimate of 6.00. The median ...

Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano Genomics, …

News. Press Releases. Research Reports. ... Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2023 Earnings Call Transcript November 8, 2023 Bionano Genomics, Inc. misses on earnings expectations. Reported ... SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.Aug 30, 2023 · SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic ... SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory …Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ...

Dec 1, 2023 · Headline. After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO) finance.yahoo.com - November 17 at 2:20 PM. Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO) and Ascendis Pharma (ASND) markets.businessinsider.com - November 16 at 11:51 PM. BNGO: Get the latest Bionano Genomics stock price and detailed information including BNGO news, historical charts and realtime prices. Indices Commodities Currencies StocksBionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting. Oct '23. Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan. Oct '23.SAN DIEGO , Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders,Get Bionano Genomics Inc (BNGO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.

Price Target and Analysts Recommendations: Three buys and one hold from analysts covering the stock. Oppenheimer's analyst Kevin DeGeeter maintained a Buy rating on February 2021, setting a price target of $15 which is approximately 75% above today´s share price of $8.59 (03/18/2021). DeGeeter expects BioNano Genomics Inc to post earnings …Bionano Genomics, Inc. (NASDAQ: BNGO) seeks to enhance shareholder value not only through exceptional business performance and practices, but also through responsible and effective communication with its shareholders. The latest company information relevant to the individual and institutional investor includes stock price and history, upcoming ...

According to data from Benzinga Pro, BioNano Genomics is trading lower by 1.6% to $1.23. BNGO has a 52-week high of $4.35 and a 52-week low of $1.16. Photo via Shutterstock.UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 ...SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company ...About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.Bionano Genomics. Market Cap. $61M. Today's Change. (4.64%) $0.07. Current Price. $1.58. Price as of November 29, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may differ ...Bionano announced today that it has priced a financing to raise an aggregate of $80.0 million in a registered offering and concurrent private placement of senior secured convertible notes due 2025 and warrants Preliminary Q3 revenue expected to be between $9.1 and $9.3 million , which wouldBionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago.

Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- 11-14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, …

– Acquisition of BioDiscove ry transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics – Total revenue of $4.7 million , a 112% year-over-year total revenue increase, driven by

Price Target and Analysts Recommendations: Three buys and one hold from analysts covering the stock. Oppenheimer's analyst Kevin DeGeeter maintained a Buy rating on February 2021, setting a price target of $15 which is approximately 75% above today´s share price of $8.59 (03/18/2021). DeGeeter expects BioNano Genomics Inc to post earnings …SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2023 and to highlight recent corporate progress.Jan 10, 2023 · SAN DIEGO , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics , Inc. (BNGO) today announced its 2023 Symposium, which is the quintessential event for the optical genome mapping (OGM) community to present its progress to the world. It will feature four consecutive days of OGM presentations Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting. Oct '23. Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan. Oct '23.SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the launch of Bionano Laboratories, a new organization that combines Bionano’s optical genome mapping (OGM) data services with the clinical testing services previously offered by Lineagen, and the launch of Bionano Laboratories’ first OGM-based laboratory developed test (LDT).SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes ...Q2 2023 revenue was $8.7 million , which represents a 30% increase over Q2 2022 Installed base of Saphyr ® systems totaled 281 as of June 30, 2023 , which represents a 43% increase over Q2 2022 Sold 7,062 nanochannel array flowcells as of June 30, 2023 , which represents a 108% increase over theBionano Announces Results from its Annual Meeting of Stockholders. SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which ...The current analyst consensus has Bionano Genomics, Inc. losing around 45 cents a share in FY2023 as sales rise nearly 30% to $35.7 million. Revenue growth is projected to accelerate by over 70% ...For the last reported quarter, it was expected that Bionano Genomics, Inc. Would post a loss of $0.90 per share when it actually produced a loss of $1.24, delivering a surprise of -37.78%.

UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the …Bionano Genomics, Inc. Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing Jan 19 Bionano Genomics, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022Latest news about Bionano Genomics, Inc. North American Morning Briefing : Caution -2- Nov. 14: DJ Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023 Nov. 08: CI Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 08: CI Bionano …We would like to show you a description here but the site won’t allow us.Instagram:https://instagram. td ameritrade advisorticker tltcompetitors of teslabest stocks for covered calls 2023 Based on BioNano Genomics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.22 million and a GAAP net loss of $31.81 million.Visualize multiple tracks of genomic data for the at-a-glance context of variant calls. NₓClinical offers multi-platform integration by: Combining current and historical molecular data from array and sequencing for sample continuity. Comparing and contrasting outputs from multiple technologies to understand the underlying biology. health insurance plans for diabeticsaccura nsx Nov 8, 2023 · SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023. Business Updates Since the End ... Bionano Genomics (BNGO-8.48%) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Here's ... pande market Following the downgrade, the current consensus from Bionano Genomics' five analysts is for revenues of US$40m in 2023 which - if met - would reflect a huge 53% increase on its sales over the past ...Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. GlobeNewswire. Jun 14, 2023 · Bionano Announces Results from its Annual Meeting of Stockholders. SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which ...